Valuation: Processa Pharmaceuticals, Inc.

Market Cap 6.06M 5.19M 4.86M 4.44M 8.39M 578M 8.46M 57.29M 22.33M 291M 22.76M 22.26M 965M P/E 2024
-0.23x
P/E 2025 -0.28x
Enterprise Value 525K 449K 421K 384K 726K 50.06M 732K 4.96M 1.93M 25.23M 1.97M 1.93M 83.55M EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
85.18%
Yield 2024 *
-
Yield 2025 -

Last Transcript: Processa Pharmaceuticals, Inc.

1 day+0.46%
1 week+2.35%
Current month+1.40%
1 month-16.15%
3 months-17.74%
6 months+12.37%
Current year-24.31%
1 week 2
Extreme 2
2.28
1 month 1.8
Extreme 1.8
3.11
Current year 1.67
Extreme 1.6701
3.8
1 year 1.67
Extreme 1.6701
14.24
3 years 1.67
Extreme 1.6701
450
5 years 1.67
Extreme 1.6701
4,495.35
10 years 1.67
Extreme 1.6701
125,195.11
Manager TitleAgeSince
Chief Executive Officer 52 2023-08-07
Investor Relations Contact 60 2011-03-28
Chief Administrative Officer 61 2017-10-03
Director TitleAgeSince
Chairman 73 2011-03-28
Chairman 60 2022-08-15
Director/Board Member 56 2020-02-12
Date Insider Type Main position Quantity % Market Cap.
8/8/26 Fiscal year

Chief Executive Officer

3,200 0.1156%
7/26/26 Other

Chief Financial Officer

11,883 0.4293%
7/26/26 Other

Chief Executive Officer

9,384 0.3390%
Change 5-day change 1-year change 3-year change Capi.($)
+0.46%+2.35%-60.00%-98.61% 6.06M
+3.31%-3.53%+71.28%+104.57% 69.06B
+1.74%+2.81%+55.45%+88.75% 63.06B
+1.09%+24.51%+2.86%-4.20% 28.34B
-0.07%-3.45%-6.06%+464.93% 27.07B
+7.41%+13.08%+58.57%+17.04% 25.45B
+3.98%+4.37%+39.87%-15.08% 19.69B
+1.02%+5.67%+273.94%+420.34% 19.19B
+0.10%+0.19%+12.19%+550.31% 15.95B
+3.98%+8.41%+46.83%+160.78% 13.52B
Average +2.30%+3.74%+49.49%+168.88% 28.13B
Weighted average by Cap. +2.52%+2.95%+59.34%+157.97%

Financials

2024 2025
Net sales - -
Net income -11.85M -10.15M -9.5M -8.68M -16.4M -1.13B -16.54M -112M -43.66M -570M -44.49M -43.52M -1.89B -13.56M -11.62M -10.87M -9.94M -18.77M -1.29B -18.93M -128M -49.97M -652M -50.93M -49.81M -2.16B
Net Debt -1.12M -958K -896K -819K -1.55M -107M -1.56M -10.56M -4.12M -53.75M -4.2M -4.11M -178M -5.54M -4.74M -4.44M -4.06M -7.66M -528M -7.73M -52.33M -20.4M -266M -20.79M -20.33M -882M
Logo Processa Pharmaceuticals, Inc.
Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of Next Generation Cancer therapy (NGC) small molecules. Its oncology pipeline consists of NGC-Cap and NGC-Iri (also identified as PCS6422 and PCS11T, respectively) and two non-oncology drugs (PCS12852 and PCS499). NGC-Cap is a combination of PCS6422 and capecitabine, capecitabine being the oral prodrug of the cancer drug 5-fluorouracil. PCS3117 is an oral analog of gemcitabine that is converted to its active metabolite by a different enzyme system than gemcitabine. PCS11T is a prodrug of the active metabolite of irinotecan. PCS12852 is a specific and potent 5HT4 agonist that is in Phase IIB and is a potential treatment for diabetic gastroparesis patients. PCS499 is a drug that can be used to treat unmet medical needs and conditions caused by multiple pathophysiological changes. Its pipelines also include VT-7208, a Bruton's tyrosine kinase inhibitor therapy for immune-mediated diseases.
Employees
12
Date Price Change Volume
26-08-25 US$2.180 +0.46% 53,553
26-08-24 US$2.170 +4.33% 30,510
26-08-21 US$2.080 -3.03% 75,971
26-08-20 US$2.145 -0.23% 27,537
26-08-19 US$2.150 +2.38% 25,072

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PCSA Stock